1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)ethanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)ethanone
• 英文别名: 1-(4-(trifluoromethyl)cyclohexyl)ethan-1-one；1-[4-(Trifluoromethyl)cyclohexyl]ethan-1-one；1-[4-(trifluoromethyl)cyclohexyl]ethanone
• 化学式: C₉H₁₃F₃O
• mdl: MFCD21775950
• 分子量: 194.197
• InChiKey: GDSXNCNUMYZWGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  甲基锂 、 trans 4-(trifluoromethyl)cyclohexane-1-carboxylic acid 以 乙醚 为溶剂， 以99%的产率得到1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)ethanone
  参考文献：
  名称：

  WO2020012423A5

  摘要：

  公开号：

  WO2020012423A5

文献信息

• [EN] ATF6 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS ATF6 ET LEURS UTILISATIONS
  申请人：BLACK BELT TX LTD

  公开号：WO2021069721A1

  公开（公告）日：2021-04-15

  Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer. (Formula (1-2))

  提供了作为激活转录因子6（ATF6）调节剂的化合物（1-2）。这些化合物可能被用作治疗由ATF6介导的疾病或紊乱的治疗剂，并且可能特别适用于治疗病毒感染、神经退行性疾病、血管疾病或癌症。 （化学式（1-2））
• 8-SUBSTITUTED IMIDAZOPYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY
  申请人：THE UNIVERSITY OF TOKYO

  公开号：US20160002247A1

  公开（公告）日：2016-01-07

  A compound of formula (I) wherein variables are as defined herein having an autotaxin inhibitory effect and a pharmaceutical composition comprising the same.

  具有自体脂肪酶抑制作用的化合物（I）的化学式，其中变量如本文所定义，并且包含该化合物的药物组合物。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME
  申请人：Shirai Junya

  公开号：US20110178060A1

  公开（公告）日：2011-07-21

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R 2 , R 3 , R 4a and R 4b are each independently a hydrogen atom, an optionally halogenated C 1-6 alkyl group or an optionally halogenated C 3-6 cycloalkyl group, or R 2 and R 3 are optionally bonded via an alkylene chain or an alkenylene chain, or R 4a and R 4b are optionally bonded via an alkylene chain or an alkenylene chain; R 1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.

  本发明涉及一种化合物，其表示为式： 其中，环A是一种含氮杂环；环B是一种芳香环，可选地具有取代基；环D是一种芳香环，可选地具有取代基；L是一个代表式为R2、R3、R4a和R4b的基团，其中R2、R3、R4a和R4b各自独立地是氢原子、可选卤代的C1-6烷基或可选卤代的C3-6环烷基，或者R2和R3通过烷基链或烯基链可选地连接，或者R4a和R4b通过烷基链或烯基链可选地连接；R1是氢原子或取代基；m和n各自独立地为0到5的整数；m+n是2到5的整数；以及为单键或双键，或其盐；等等。该化合物具有优良的缩氨酸受体拮抗作用，并可用作预防或治疗各种疾病的药剂，如下尿路疾病、消化道疾病、中枢神经系统疾病等。
• Biaryl pyrazoles as NRF2 regulators
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10364256B2

  公开（公告）日：2019-07-30

  The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

  本发明涉及式（I）的双芳基吡唑化合物 的制造方法、含有它们的药物组合物以及它们作为 NRF2 调节剂的用途。
• WO2020012423A5
  申请人：——

  公开号：WO2020012423A5

  公开（公告）日：2022-07-20